- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines of Therapy
August 28th 2022, 2:51pm
International Myeloma Society Annual Meeting
Ciltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.
Dr. Cohen on the Efficacy of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma
August 28th 2022, 2:37pm
Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.
Dr. Raje on the Utilization of bb21217 in Relapsed/ Refractory Multiple Myeloma
August 28th 2022, 2:37pm
Noopur Raje, MD, discusses the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.
Biallelic Deletion of TNFRSF17 Associated With Resistance to BCMA-Targeting Therapies In Myeloma
August 28th 2022, 2:36pm
International Myeloma Society Annual Meeting
Identifying BCMA expression, copy number variation, and point mutations can have important therapeutic implications for patients receiving BCMA-targeting CAR T-cell therapy or T-cell engagers for multiple myeloma.
Daratumumab Plus RVd Improves Clinical Outcomes in Transplant-Eligible, Newly Diagnosed Multiple Myeloma
August 28th 2022, 1:27am
International Myeloma Society Annual Meeting
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and consolidation treatment and lenalidomide maintenance therapy (D-RVd/D-R) resulted in high minimal residual disease rates and prolonged progression-free survival in patients with transplant-eligible, newly diagnosed multiple myeloma.
Busulfan/Melphalan Prior to ASCT Fails to Elicit PFS Benefit in Newly Diagnosed Myeloma
August 28th 2022, 1:00am
International Myeloma Society Annual Meeting
High-dose busulfan plus melphalan failed to generate a progression-free survival benefit vs melphalan for autologous stem cell transplant conditioning in patients with newly diagnosed multiple myeloma after induction therapy.
Bispecific Antibody ABBV-383 Looks to Fill Unmet Need in Heavily Pretreated Multiple Myeloma
August 28th 2022, 12:49am
International Myeloma Society Annual Meeting
Promising safety and efficacy results were observed with the novel bispecific antibody ABBV-383 in patients with heavily pretreated relapsed or refractory multiple myeloma.
Relapse Following CAR T-cell Therapy Linked to Poor OS in Relapsed/Refractory Myeloma
August 27th 2022, 7:55pm
International Myeloma Society Annual Meeting
Relapse following treatment with BCMA-directed CAR T-cell therapy was associated with poor survival outcomes in patients with relapsed/refractory multiple myeloma.
Isatuximab Plus Pomalidomide/Dexamethasone Maintains OS Benefit in R/R Myeloma
August 27th 2022, 6:30pm
International Myeloma Society Annual Meeting
The addition of isatuximab to pomalidomide and low-dose dexamethasone continued to demonstrate improved overall survival in patients with relapsed/refractory multiple myeloma.
Isatuximab Plus Kd Demonstrates Deep Responses in Relapsed Multiple Myeloma
August 27th 2022, 5:36pm
International Myeloma Society Annual Meeting
The addition of isatuximab to carfilzomib and dexamethasone elicited a clinically meaningful improvement in depth of response in patients with relapsed multiple myeloma.
REGN5458 Elicits Promising Responses, Safety in Relapsed/Refractory Myeloma
August 27th 2022, 5:24pm
International Myeloma Society Annual Meeting
REGN5458 produced durable responses with low rates of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.
Multiple Myeloma Armamentarium Is Set to Explode as Novel Agents Show Encouraging Early Data
August 27th 2022, 5:21pm
International Myeloma Society Annual Meeting
Agents with novel mechanisms, including bispecific antibodies, immunomodulatory drugs, and antibody-drug conjugates, are displaying promising results in patients with relapsed or refractory multiple myeloma.
Dr. Richardson on Isatuximab Plus Pomalidomide/Dexamethasone in R/R Myeloma
August 27th 2022, 2:10pm
Paul G. Richardson, MD, discusses the overall survival benefit displayed by isatuximab plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.
Dr. Puertas‐Martinez on Carfilzomib and Dexamethasone plus Cyclophosphamide in Multiple Myeloma
August 27th 2022, 2:10pm
Borja Puertas‐Martinez, MD, discusses the use of carfilzomib and dexamethasone with or without cyclophosphamide in patients with relapsed/refractory multiple myeloma.
Cevostamab Elicits Responses in Younger and Older Patients with Relapsed/Refractory Myeloma
August 27th 2022, 2:04pm
International Myeloma Society Annual Meeting
Cevostamab generated responses and was well tolerated in younger and older patients with relapsed/refractory multiple myeloma.
Ocular Toxicity With Belantamab Mafodotin Is Not Influenced by Baseline Ocular Conditions in R/R Myeloma
August 27th 2022, 1:53pm
International Myeloma Society Annual Meeting
Baseline ocular conditions not related to the cornea have little effect on treatment-emergent adverse effects that may arise with belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
Isatuximab Under Evaluation in Real-World Study in Relapsed/Refractory Multiple Myeloma
August 27th 2022, 12:46pm
International Myeloma Society Annual Meeting
Treatment with standard-of-care isatuximab in patients with relapsed/refractory multiple myeloma is being evaluated in a real-world trial,
Post-Transplant Carfilzomib Plus Lenalidomide/Dexamethasone Provides Superior PFS Benefit Over Lenalidomide in Myeloma
August 26th 2022, 9:54pm
International Myeloma Society Annual Meeting
Extended treatment with carfilzomib plus lenalidomide and dexamethasone after autologous stem cell transplant improved progression-free survival over standard lenalidomide maintenance in patients with multiple myeloma.
Isatuximab Plus Carfilzomib/Dexamethasone Maintains Survival Benefit in Relapsed Multiple Myeloma
August 26th 2022, 9:45pm
International Myeloma Society Annual Meeting
The combination of Isatuximab plus carfilzomib and dexamethasone continued to demonstrate a progression-free survival benefit vs carfilzomib and dexamethasone alone in relapsed multiple myeloma.
Lenalidomide Combo Plus ASCT Provides Significant PFS Benefit in Multiple Myeloma With High-Risk Cytogenetics
August 26th 2022, 9:39pm
International Myeloma Society Annual Meeting
The triplet regimen of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation and lenalidomide maintenance therapy significantly improved progression-free survival compared with RVd alone in patients with newly diagnosed multiple myeloma, with notable benefit observed in those with high-risk cytogenetics.